7046-40-4

Prostaglandin E₁ (PGE₁) is not a major naturally occurring prostaglandin, but it is widely administered clinically for several indications including peripheral occlusive vascular disease, erectile dysfunction and in neonatal cardiology.^1,2 The metabolism of PGE₁ is normally initiated by oxidation at C-15, resulting in 13,14-dihydro-15-keto PGE₁ as the major metabolite. However, inhibition of this pathway or saturation by excess substrate could theoretically lead to enhanced production of 2,3-dinor metabolites, including 2,3-dinor PGE₁. The biological activity of 2,3-dinor PGE₁ has not been published. Cayman Chemical is a leading supplier of prostaglandins and their metabolites, and is currently the exclusive manufacturer of 2,3-dinor PGE₁.

ChEBI: 2,3-Dinor-PGE1 is a prostanoid.

1. Virag, R., Shoukry, K., Floresco, J., et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-Year experience with 615 cases J. Urol. 145(2),287-293(1991).
2. Hoshi, K. Approved indications of lipo-PGE₁ in Japan Adv. Drug Deliv. Rev. 20(2-3),171-176(1996).